The Opportunity Behind This Medicine

Psilocybin mushrooms have risen in popularity to treat depression over the past few years. Now this market sees even more upside ahead.‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

SPONSORED There's a Reason The Washington Post Calls 5G "The Mother of Invention"... And it's not just that your internet will be faster. 5G will power technologies that were UNTHINKABLE a few years ago. We're talking about driverless cars, remote surgery, holograms... The possibilities are LIMITLESS. So if you don't own any 5G stocks, you could miss out BIG-TIME. Click here for details on the No. 1 5G stock for 2021. Editor's Note: It's a fact of life: We're all getting older. Research shows that your brain loses its strength and elasticity over the course of your life. That means memory and motor functions get worse with age. You may have noticed this with older friends or family, or even in yourself. In time, it may be possible to stimulate growth for those brain cells and rebuild with something that Chief Trends Strategist Matthew Carr likes to call "Living Medicine." The atoms in this substance are truly alive. If the early findings are correct, this medicine could be as transformative to our society as penicillin! And even better, its market is projected to grow at an annual rate of 16.3% over the next eight years, reaching $6.85 BILLION by 2027. What are you waiting for? Learn more here. - Kaitlyn Hopkins, Assistant Managing Editor MARKET TRENDS The $100 Billion Opportunity Behind Psilocybin Mushrooms Matthew Carr | Chief Trends Strategist | The Oxford Club Throughout much of human history, mental illness has been grossly misunderstood. And the so-called treatments ranged from ludicrous to barbaric. The ancient Greek physician Hippocrates believed depression - or what he referred to as "melancholia" - was caused by an imbalance of the four bodily fluids: yellow bile, black bile, phlegm and blood. He believed too much black bile in the spleen caused depression. To remedy this, he recommended bloodletting and baths. Aulus Cornelius Celsus, who wrote the famed De Medicina, believed in beatings, leg-irons and starvation to treat mental illness... anything that would stir up the spirit. Fast-forward nearly 2,000 years and treatments haven't gotten much better. In the 20th century, doctors used electroconvulsive therapy and lobotomies to treat depression. It wasn't until the 1950s that people noticed the tuberculosis medication Isoniazid appeared to help some patients suffering from depression. And over the next several decades, we saw the emergence of tricyclic antidepressants (TCAs) - like Anafranil, Norpramin and Tofranil - as well as selective serotonin reuptake inhibitors (SSRIs), like Celexa, Lexapro, Prozac and Paxil. These have helped millions of patients and have created billions of dollars in revenue for companies. But we're still facing a crisis. Depression is the leading cause of disability worldwide. And it's a major contributor to the overall burden of disease globally. For instance, in the U.S., the annual cost of depression is more than $200 billion. Not to mention that depression can lead to suicide. And more than 800,000 people around the world take their own lives each year. Even worse, there's treatment-resistant depression (TRD). Antidepressants and counseling help ease the symptoms of depression for many people. They can help people manage the illness and live a "normal" life. But for others, these simply don't work. So not only does TRD impact a person's quality of life, but it's also a financial burden, as there's a constant need for tweaks. Just in the U.S., TRD patients face medical costs two to three times those of other major depression sufferers. But here's the truly staggering figure: It's estimated that almost one-third of all patients with major depressive disorder suffer from TRD. Thankfully, there is potential salvation for patients as well as a massive upside for investors. And the roots of this treatment can actually be traced back further than Celsus' De Medicina. SPONSORED 5G Stock CRUSHES Earnings!! Wall Street is loading up on shares of one 5G SuperStock (with more than $2 billion invested!). Why? Because the stock brings in more cash than IBM, Facebook and even Google! Yet it trades for just $3. Get the scoop on the 5G SuperStock right here.   A New Class of Antidepressants As far back as 9000 B.C., humans have been consuming "magic mushrooms." A little more than 8% of the U.S. population has used them, whether they were used for spiritual trips, medical relief or recreational purposes. The active ingredient, psilocybin - which is the engine for all the visual and auditory hallucinations - activates the serotonin receptors in the prefrontal cortex of the brain. This impacts mood, cognition and perception. We're on the cusp of a new era of medicine. And it's, in part, thanks to those hallucinations. Now, the neurotransmitters, the monoamines - dopamine, norepinephrine and serotonin - are what antidepressants target. In people with depression, these neurotransmitters are in low quantities. Besides TCAs and SSRIs, there are also serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs) and atypical antidepressants, like Wellbutrin. SSRIs and SNRIs are the most commonly prescribed. And that's because over the past several decades, we've found serotonin's role is center stage in treating depression. Here's where it gets interesting... Starting in 2016, a study from Johns Hopkins University demonstrated that patients treated with psilocybin saw an effect "about four times larger than what clinical trials have shown for traditional antidepressants on the market." And in October 2018, the U.S. Food and Drug Administration awarded the "Breakthrough Therapy" designation to psilocybin to treat TRD. This was a major milestone for psilocybin and the 100 million TRD patients suffering around the globe. And the company granted this designation was Compass Pathways (Nasdaq: CMPS). Its COMP360 drug is currently in clinical trials, which are expected to be completed later this year. Compass was founded in 2016 to accelerate patient access to innovative treatments, such as psilocybin. Between going public last year and around March of this year, shares of the life sciences company decimated the market. Shares have hit a rough patch recently, mostly because its performance is mirroring that of the AdvisorShares Pure US Cannabis ETF (NYSE: MSOS). With Washington, D.C., dragging its feet on cannabis legalization, it's brought the broader psychedelic medicine market down with it. But the sector is still seeing advances and is reporting great numbers. And that makes these lows such an attractive entry point. Treatments like COMP360 could be a major turning point. And there's potentially a lot more on the horizon... Preclinical research is being conducted on using psilocybin to treat Alzheimer's, attention deficit hyperactivity disorder, autistic spectrum disorder, cluster headaches, chronic pain, eating disorders, epilepsy, obsessive-compulsive disorder, Parkinson's, sleep-wake disorders and general anxiety. At the moment, the projected market for psilocybin and other psychedelic medicines could top $100 billion. And the push to legalize psilocybin in the U.S. and Canada has already begun. As a trends expert, I think the psilocybin market is where the cannabis market was five to 10 years ago. But the upside is much different. We're witnessing a new class of antidepressants be born. And that could have a far larger impact than we can realistically put a price tag on. Here's to high returns, Matthew P.S. If you're interested in learning more about the companies that are profiting off psilocybin's medical uses, learn how to gain access to my special reports by clicking here. P.P.S. If you or someone you know is struggling with depression or suicidal thoughts, call the National Suicide Prevention Lifeline at 1.800.273.8255. Leave a Comment MORE FROM PROFIT TRENDS Should You Buy This Cannabis SPAC? Navigate a Rocky Stock Market With Inverse ETFs Electric Reefers Will Soon Hit the Roads Facebook Twitter Email Share SPONSORED He's got an 83% win rate... And he's guaranteeing he beats it over the next year! You won't believe it until you see how it works so well. You are receiving this email because you subscribed to Profit Trends. Profit Trends is published by The Oxford Club. Ready to start investing? Click here now. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Profit Trends | Unsubscribe © 2021 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 1.800.589.3430 | International: +1.443.353.4334 | Fax: 1.410.329.1923 Oxfordclub.com The Oxford Club is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that although our track record is highly rated by an independent analysis and has been legally reviewed, investment markets have inherent risks and there can be no guarantee of future profits. The stated returns may also include option trades. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publications prior to following an initial recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, 105 W. Monument Street, Baltimore MD 21201.